Clinical Research Directory
Browse clinical research sites, groups, and studies.
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion
Sponsor: National Cancer Institute (NCI)
Summary
This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub off and can be associated with a higher risk of cancer. Metformin hydrochloride may help prevent oral cancer from forming in patients with an oral premalignant lesion.
Official title: M4OC-Prevent: Metformin for Oral Cancer Prevention
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
26
Start Date
2016-06-10
Completion Date
2026-12-19
Last Updated
2026-04-09
Healthy Volunteers
No
Interventions
Laboratory Biomarker Analysis
Correlative studies
Metformin Hydrochloride
Given PO
Locations (4)
UC San Diego Medical Center - Hillcrest
San Diego, California, United States
University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, United States
BC Cancer Research Centre
Vancouver, British Columbia, Canada
University of British Columbia Hospital
Vancouver, British Columbia, Canada